# Ontwikkeling van linkerventrikelhypertrofie bij behandelde hypertensie: Campania Salute Network

*geplaatst 2017-01-01 · Hypertensie · Hypertension (Dallas, Tex. : 1979) · doi 10.1161/HYPERTENSIONAHA.116.08158 · https://hartvaat.nl/2017/01/01/ontwikkeling-van-linkerventrikelhypertrofie-bij-behandelde-hypertensie-campania-/*

Studie naar de ontwikkeling van linkerventrikelhypertrofie bij poliklinisch behandelde hypertensieve patiënten ondanks therapie. Identificeert risicofactoren voor progressieve orgaanschade.

## English: Development of Left Ventricular Hypertrophy in Treated Hypertensive Outpatients: The Campania Salute Network.

This study documented the development of new left ventricular hypertrophy in treated hypertensive outpatients, showing that LVH can progress despite blood pressure therapy and identifying predictors of treatment failure.

## Abstract (original, from the publication)

UNLABELLED: There is little information on left ventricular (LV) hypertrophy (LVH) development during antihypertensive treatment. We evaluate incident LVH in a treated hypertensive cohort, the Campania Salute Network registry. We analyzed prospectively 4290 hypertensives (aged 50.3±11.1 years, 40% women) with at least 1-year follow-up, without LVH at baseline. Incident LVH was defined as the first detection of echocardiographic LV mass index ≥47 in women or ≥50 g/m2.7 in men. During a median 48-month follow-up, 915 patients (21.3%) developed LVH. They were older, more frequently women, and obese (P<0.0001), with initial higher fasting glucose, diastolic and systolic blood pressure, LV mass index, lower heart rate and glomerular filtration rate, longer hypertension history and follow-up, and higher average systolic blood pressure during follow-up (all P<0.05), despite a more frequent treatment with Ca++-channel blockers and diuretics (both P<0.02). At multivariable Cox regression, incident LVH was independently associated with older age, female sex, obesity, higher average systolic blood pressure during follow-up, and initial greater LV mass index (all P<0.02). By categorizing patients according to obesity and sex, obesity independently increased the risk for incident LVH in both sexes (obese versus nonobese men: hazard ratio, 1.34; confidence interval, 1.05-1.72; P=0.019; and obese versus nonobese women: hazard ratio, 1.34; confidence interval, 1.08-1.66; P=0.007). Despite more aggressive antihypertensive therapy, 21% of hypertensive patients develop clear-cut LVH. After adjusting for confounders, risk of incident LVH is particular relevant among women and is further increased by the presence of obesity. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02211365.

Auteurs: Raffaele Izzo, Maria-Angela Losi, Eugenio Stabile, Mai Tone Lönnebakken, Grazia Canciello, Giovanni Esposito, Emanuele Barbato, Nicola De Luca, Bruno Trimarco, Giovanni de Simone

---
Bron: Hypertension (Dallas, Tex. : 1979), https://doi.org/10.1161/HYPERTENSIONAHA.116.08158. Bijgewerkt 2026-07-03T18:38:29Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.